Aerial BioPharma Receives FDA Orphan Drug Designation for Narcolepsy Drug in Development

Published: Aug 29, 2012

MORRISVILLE, N.C.--(BUSINESS WIRE)--Aerial BioPharma, a biopharmaceutical company focused on developing biologics and small molecules for conditions in the central nervous system, has received orphan drug designation for its narcolepsy drug in development.

Back to news